Medical Oncology

Prof. Dr. Emel Sezer

Doctor and researcher Medical Park Mersin Mersin
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedicalpark.com.trFrom source
  • Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
  • InstitutionMedical Park Mersinmedicalpark.com.trFrom source
  • Area of workBreast NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications36 publicationsEurope PMC, OpenAlexFrom source
  • ORCID0000-0001-9881-3533ORCIDFrom source
  • Last synchronised4 November 2026 20:26https://www.medicalpark.com.tr/hekimler/emel-sezermedicalpark.com.tr

Scientific work

Publications on Breast Neoplasms

36 publications
Publications by year Most: 6, in 2018
  1. 2014: 1 publication
  2. 2015: 1 publication
  3. 2016: 1 publication
  4. 2017: 4 publications
  5. 2018: 6 publications
  6. 2019: 5 publications
  7. 2020: 1 publication
  8. 2021: 3 publications
  9. 2022: 5 publications
  10. 2023: 4 publications
  11. 2024: 1 publication
  12. 2025: 1 publication
  13. 2026: 3 publications

  1. Prognostic impact of c-MYC and EZH2 expression in small cell and non-small cell lung carcinoma: a single-center retrospective study

    Discover oncology, 2026

    DOI 10.1007/s12672-026-04941-1 PMID 41928013 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  2. Acupressure for oncology symptom management during chemotherapy: A three-arm randomized controlled trial of therapist versus self-application

    European Journal of Integrative Medicine, 2026

    DOI 10.1016/j.eujim.2026.102654 Source: OpenAlex

  3. Evaluation of Treatment Response in Prostate Cancer Patients: Analysis of Ga-68 PSMA PET/CT Parameters According to PROMISE Criteria

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-8-6 Open-access full textSource: OpenAlex

  4. Abstract P5-12-17: Breast MRI and FDG-PET/CT for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer

    Clinical Cancer Research, 2025

    DOI 10.1158/1557-3265.sabcs24-p5-12-17 Source: OpenAlex

  5. The quantification for the treatment response evaluation of Metastatic Gastroenteropancreatic Neuroendocrine Tumors in Ga-68 DOTATATE PET/CT

    DergiPark (Istanbul University), 2024

    Open-access full textSource: OpenAlex

  6. Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.4_suppl.550 5 citations (OpenAlex) Source: OpenAlex

  7. F-18 FDG PET/CT in a Soft Tissue Tumor with Pericardial Metastasis

    DergiPark (Istanbul University), 2023

    Open-access full textSource: OpenAlex

  8. Mortality Analysis by Means of F-18 FDG PET/CT in High Grade Extranodal Head and Neck Lymphoma

    DergiPark (Istanbul University), 2023

    Open-access full textSource: OpenAlex

  9. The Role of lncRNA H19 in the Resistance of Ovarian Cancer Cells to Cisplatin Therapy

    Mersin Üniversitesi Açık Erişim Sistemi/Mersin University Open Access System, 2023

    Open-access full textSource: OpenAlex

  10. Gastrointestinal Sistem Kanserlerinde Güncel Yaklaşımlar Yazarlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.984 Open-access full textSource: OpenAlex

View all 36 publications